High agreement of Seegene Anyplex™ HPV 28 and Allplex™ HPV 28 for high-risk vaccine-type HPV detection in the KEN SHE Study.

Saved in:
Bibliographic Details
Title: High agreement of Seegene Anyplex™ HPV 28 and Allplex™ HPV 28 for high-risk vaccine-type HPV detection in the KEN SHE Study.
Authors: Heller KB; Massachusetts General Hospital, Infectious Diseases Division, Boston, MA, United States of America. Electronic address: kheller@mgh.harvard.edu., Mohamed JS; University of Nairobi/University of Washington, East Africa STI Laboratory, Mombasa, Kenya., Cherne SL; University of Washington, Department of Laboratory Medicine and Pathology, Seattle, WA, United States of America., Onono M; Kenya Medical Research Institute, Center for Microbiology Research, Kisumu, Kenya., Bukusi EA; Kenya Medical Research Institute, Center for Microbiology Research, Kisumu, Kenya; University of Washington, Department of Obstetrics and Gynecology, Seattle, WA, United States of America; Universityof Washington, Department of Global Health, Seattle, WA, United States of America., Njoroge BW; Kenya Medical Research Institute, Center for Clinical Research, Nairobi, Kenya., Kimanthi S; Kenya Medical Research Institute, Center for Clinical Research, Nairobi, Kenya., Hassan RM; University of Nairobi/University of Washington, East Africa STI Laboratory, Mombasa, Kenya., Rechkina EA; Universityof Washington, Department of Global Health, Seattle, WA, United States of America., McClelland RS; University of Nairobi/University of Washington, East Africa STI Laboratory, Mombasa, Kenya; Universityof Washington, Department of Global Health, Seattle, WA, United States of America; University of Washington, Department of Epidemiology, Seattle, WA, United States of America; University of Washington, Department of Medicine, Division of Allergy and Infectious Diseases, Seattle, WA, United States of America., Brown ER; University of Washington, Department of Biostatistics, Seattle, WA, United States of America; Fred Hutchinson Cancer Center, Vaccine and Infectious Disease Division, Seattle, WA, United States of America; Fred Hutchinson Cancer Center, Public Health Sciences, Seattle, WA, United States of America., Mugo NR; Universityof Washington, Department of Global Health, Seattle, WA, United States of America; Kenya Medical Research Institute, Center for Clinical Research, Nairobi, Kenya., Barnabas RV; Massachusetts General Hospital, Infectious Diseases Division, Boston, MA, United States of America; Harvard Medical School, Department of Medicine, Boston, MA, United States of America; Harvard School of Public Health, Department of Epidemiology, Boston, MA, United States of America.
Corporate Authors: KEN SHE Study Team
Source: Journal of virological methods [J Virol Methods] 2026 Jul; Vol. 344, pp. 115395. Date of Electronic Publication: 2026 Apr 08.
Publication Type: Journal Article; Randomized Controlled Trial; Comparative Study
Journal Info: Publisher: Elsevier/North-Holland Biomedical Press Country of Publication: Netherlands NLM ID: 8005839 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0984 (Electronic) Linking ISSN: 01660934 NLM ISO Abbreviation: J Virol Methods Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1879-0984
DOI:10.1016/j.jviromet.2026.115395